Salivary Gland Tumor clinical trials at UCSF
1 research study open to eligible people
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
open to eligible people ages 18 years and up
An open-label, multi-center, single and cyclic ascending dose study of P-PSMA-101 autologous CAR-T cells in patients with mCRPC and SGC.
San Francisco, California and other locations
Our lead scientists for Salivary Gland Tumor research studies include David Oh.